Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes. Circulating tumor DNA (ctDNA) has ...
Triple-negative breast cancer (TNBC), the most aggressive subtype, poses a significant challenge as approved targeted therapies are lacking. The epidermal growth factor receptor (EGFR) is highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results